Heimann G, von Heereman B, Gladtke E
Arzneimittelforschung. 1979;29(12a):1949-51.
In 13 newborns and 12 prematures the pharmacokinetic parameters of 6-[(R)-2-(2-oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-penicillanic acid sodium salt (azlocillin, Securopen), were investigated after a single i.v. load of 50 mg/kg body weight. From the concentration-time curve an open two-compartment model could be postulated. The values of the microconstants indicate that there is a rapid diffusion from the peripheral compartment into the central one. The elimination half-life calculated from the beta-slope is 2.6-2.5 h. differences between newborns and prematures are lacking. To reach an average steady-state concentration C-infinity between 50 and 80 microgram/ml plasma, 100-200 mg azlocillin/kg body weight during 24h must be given. The accumulation rates for a dosage interval of 6 or 8 h are 0.6 and 0.45.
对13名新生儿和12名早产儿在静脉单次负荷给予50mg/kg体重的6-[(R)-2-(2-氧代-咪唑烷-1-甲酰胺基)-2-苯基-乙酰胺基]-青霉烷酸钠盐（阿洛西林，苯咪唑青霉素）后，研究了其药代动力学参数。从浓度-时间曲线可推测为开放性二室模型。微常数的值表明存在从周边室向中央室的快速扩散。根据β斜率计算的消除半衰期为2.6 - 2.5小时。新生儿和早产儿之间无差异。为使血浆平均稳态浓度C∞达到50至80μg/ml，必须在24小时内给予100 - 200mg阿洛西林/kg体重。给药间隔为6或8小时时的蓄积率分别为0.6和0.45。
